Ratings Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Market Closed - Nyse Other stock markets 04:00:02 2024-05-10 pm EDT			5-day change	1st Jan Change
15.41 ^USD	+0.78%		+13.31%	-9.67%

May. 06	Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	MT
May. 06	Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company appears to be poorly valued given its net asset value.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
BAUSCH + LOMB CORPORATION	-9.67%	5.42B	-
ABBOTT LABORATORIES	-4.84%	182B	C+
MEDTRONIC PLC	+0.56%	110B	C
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B	A
DEXCOM, INC.	+2.39%	50.53B	B-
CENCORA, INC.	+9.36%	44.8B	B-
HOYA CORPORATION	+2.70%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.3B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B	A-
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes